IP Library Granted Patent US 9,902,688
Granted Patent B2
US 9,902,688 · App. 15/151,413 · Granted Feb 27, 2018

Benzamides and nicotinamides as Syk modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,688
App. No.
15/151,413
Granted
Feb 27, 2018
Kind
B2
Abstract

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

Claims (12)

1. A compound selected from the group consisting of

2. A composition of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.

3. A method for treating a condition or disease selected from the group consisting of a hematological malignancy, rheumatoid arthritis, systemic lupus erythematosus, asthma, and Type 1 diabetes in a subject comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1 .

4. The method of claim 3 , wherein said condition or disease is selected from the group consisting of asthma, systemic lupus erythematosus, and Type I diabetes.

5. The method of claim 3 , wherein said disease is rheumatoid arthritis.

6. The method of claim 3 , wherein said hematological malignancy is selected from the group consisting of acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma.

7. A kit comprising a composition of claim 2 , packaging and instructions for use.

8. The compound of claim 1 , having the formula

9. The compound of claim 1 , having the formula

10. The compound of claim 1 , having the formula

11. The compound of claim 1 , having the formula

12. The compound of claim 1 , having the formula

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: PORTOLA PHARMACEUTICALS, LLC
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 054999/0218 →
CHANGE OF NAME Recorded Jan 12, 2021
From: PORTOLA PHARMACEUTICALS, INC.
To: PORTOLA PHARMACEUTICALS, LLC
Reel/Frame 054975/0183 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: HCR COLLATERAL MANAGEMENT, LLC
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 053120/0925 →
SECURITY INTEREST Recorded Mar 18, 2019
From: PORTOLA PHARMACEUTICALS, INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 048633/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2016
From: JIA, ZHAOZHONG J.; SONG, YONGHONG; XU, QING; KANE, BRIAN; BAUER, SHAWN M.; PANDEY, ANJALI
To: PORTOLA PHARMACEUTICALS, INC.
Reel/Frame 039032/0960 →